Redx Pharma: With two wholly-owned assets in the clinic there are now plenty of catalysts

0
8
  • RedX Pharma hails strong progress with drug candidate pipeline in first half
  • Redx Pharma strikes balance between in-house programmes and partnerships
  • Full interview: RedX Pharma drug candidate pipeline underpins strong first half progress
researcher at microscope

Quick facts: Redx Pharma PLC

Follow

View company profile

Redx is a biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept (PoC).

07 Jun 2021

RedX Pharma PLC (LON:REDX) chief executive Lisa Anson has hailed “strong progress” with the company’s pipeline of drug candidates in the first half of its current year.

In its results for the six months to March 31, the drug discovery and development firm said it has successfully completed dosing of the first four patient cohorts in a Phase 1 clinical trial of its lead oncology asset, RXC004, adding that post-period it has also initiated a second clinical programme for RXC007, a selective Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor for development in idiopathic pulmonary fibrosis and potentially other fibrotic conditions.

The firm also said it has “significantly progressed” its partnered programs with Jazz Pharmaceuticals, as well as undertaken a number of board changes including the appointment of a chief medical officer and chief financial officer.

Looking ahead, RedX said it benefited from increased financial strength during the first half, and that it expects to successfully complete the Phase 1 study of RXC004 “very soon” which will allow it to select an appropriate dose to begin Phase 2 studies in the second half of 2021.

Read more

03 Jun 2021

Redx Pharma PLC (AIM:REDX), the drug discovery and development company, said the first subject has been dosed in a Phase 1 study in healthy volunteers evaluating its fibrosis drug candidate RXC007.

Candidate RXC007, which is being developed to treat fibrosis, is being administered to healthy volunteers to assess its safety and tolerability and also the way it interacts with the body.

Read more

01 Jun 2021

Redx Pharma PLC (LON:REDX), the drug discovery and development company focused on cancer and fibrosis, said non-executive chairman Iain Ross is stepping down from his role as a director.

Peter Presland, currently a non-executive director of Redx, has been appointed as interim chairman with immediate effect.

Read more

11 Sep 2020

Redx Pharma PLC (LON:REDX) is comfortable after having found a balance between in-house programmes and partnerships with other companies.

This week the biotech announced a collaboration, the first of this kind since its creation in 2010, with US company Jazz Pharmaceuticals to discover and develop two targeted cancer therapies.

Read more

07 Jun 2021

RedX Pharma PLC (LON:REDX) CEO Lisa Anson has hailed “strong progress” with the company’s pipeline of drug candidates in the first half of its current year. Anson tells Proactive London about RedX’s two clinical assets in progress, as well as fleshing out details on working partnership benefits. In its latest results, RedX said it had successfully completed dosing of the first four patient cohorts in a Phase 1 clinical trial of its lead oncology asset, adding that post-period it has also initiated a second clinical programme for a selective inhibitor for development in idiopathic pulmonary fibrosis and possibly other fibrotic conditions.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: RedX Pharma drug candidate pipeline underpins strong first…

RedX Pharma PLC (LON:REDX) CEO Lisa Anson has hailed “strong progress” with the company’s pipeline of drug candidates in the first half of its current year. Anson tells Proactive London about RedX’s two clinical assets in progress, as well as fleshing out details on working partnership benefits….

4 hours, 21 minutes ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here